Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 516 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... May 19, 2021 A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk... March 23, 2022 Colorectal Cancer Screening: The Silver Lining September 1, 2020 Load more HOT NEWS Pride 2023: Taking on the inequalities in LGBTQ+ cancer care FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast... ESMO Asia Congress 2022, 2-4 December 2022 Zanubrutinib’s Approval Improves Targeted Treatment for CLL
